The KRT7 monoclonal antibody is produced using hybridoma technology. This involves fusing B cells from the spleen of a mouse immunized with a synthesized peptide derived from human KRT7 with myeloma cells. The resulting hybridoma cells are screened for clones that produce KRT7 antibodies. These selected hybridoma cells are then cultured in the mouse abdominal cavity to produce KRT7 monoclonal antibodies. The KRT7 monoclonal antibody is purified from mouse ascites using affinity chromatography with a specific immunogen to ensure its purity. This purified antibody has been validated for use in ELISA and IHC applications.
KRT7 is primarily expressed in epithelial cells, such as those lining the bladder, gastrointestinal tract, and bile ducts. Its main function is to provide structural support to these cells and maintain their mechanical integrity. KRT7 has been shown to play a role in cell signaling, cell differentiation, and cell migration. It has also been implicated in the development of certain types of cancer.
Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on cells . They are produced by identical immune cells that are all clones of a unique parent cell . Monoclonal antibodies can be classified based on their source and structure:
Monoclonal antibodies exhibit several key biological properties:
Monoclonal antibodies play crucial roles in the immune system:
Monoclonal antibodies interact with other molecules and cells through various mechanisms:
The expression and activity of monoclonal antibodies are tightly regulated:
Monoclonal antibodies have a wide range of applications in biomedical research and medicine: